Transdermal patch tailors antinausea treatment.
Morrow
Thomas
T
Value-based Health Department, Genentech Inc., USA.
D000279:Administration, Cutaneous; D000932:Antiemetics / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000145:classification; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D017829:Granisetron / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008329:Managed Care Programs; D008495:Medical Oncology; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D064729:Neurokinin-1 Receptor Antagonists; D011292:Premedication; D058830:Serotonin 5-HT2 Receptor Antagonists
D000932:Antiemetics; D000970:Antineoplastic Agents; D017829:Granisetron; D064729:Neurokinin-1 Receptor Antagonists; D058830:Serotonin 5-HT2 Receptor Antagonists